secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041320
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q2 net loss $29.6M ($0.78/sh); cash $196.3M; LIFT-AD results H2 2024
--------------------------------------------------------------------------------

- Net loss $29.6M ($0.78/sh) vs $24.3M ($0.65/sh) in Q2 2022; R&D spend rose to $21.6M.
- Cash, cash equivalents and investments $196.3M at June 30, 2023, down from $245.2M at Dec 31, 2022.
- Completed end-of-Phase 2 FDA meeting for fosgonimeton; LIFT-AD topline expected H2 2024.
- Appointed Andrew Gengos as CFO and Chief Business Officer.
- IND-enabling studies for ATH-1105 continue; first-in-human studies targeted H1 2024 for ALS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/0000950170-23-041320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/atha-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer